Analysis of CD81-PGRL complex on T cells
T 细胞上 CD81-PGRL 复合物的分析
基本信息
- 批准号:7047887
- 负责人:
- 金额:$ 24.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-04-01 至 2008-03-31
- 项目状态:已结题
- 来源:
- 关键词:CD antigensT lymphocytebiological signal transductioncalcium fluxcyclic AMPfatty acylationhuman tissueimmunoprecipitationlaboratory mouseleukocyte activation /transformationleukocyte adhesion moleculesmass spectrometrymembrane proteinspalmitatesprostaglandin Eprostaglandin receptorprotein kinase Ctranscription factor
项目摘要
DESCRIPTION (provided by applicant): CD81 is a tetraspanin with several immunoregulatory functions. On T cells antibody to CD81 activates LFA-1 and can provide co-stimulatory signals with TCR/CD3 to promote T cell activation. Antibody to CD81 can also block early T cell development. CD81-/- mice have impaired Th2 responses and are resistant to allergen induced airway hyperreactivity. CD81 is a receptor for the hepatitis C virus (HCV) envelope protein E2, and binding of E2 to CD81 induces effects similar to those caused by anti-CD81 antibodies. The mechanism by which CD81 regulates T cell activity is unknown. It was recently discovered that on T cells CD81 is physically associated with a novel Ig-superfamily member called PGRL. PGRL may regulate prostaglandin (PG) responses on T cells. In broad terms this proposal seeks evidence of a connection between specific PGs, CD81 and the regulation of T cell adhesion and motility via LFA-I. Specifically this project will: 1) Identify the CD81-mediated signals that cause LFA-1 activation on T cells. The role of palmitoylation and the recruitment of a specific scaffold protein involved in signal transduction will be studied. A novel LFA-1 avidity assay using flow cytometry and ICAM-coated fluorescent microspheres will be used to identify signaling intermediates between CD81 and LFA-1. 2) Define the structural and molecular features of CD81-PGRL complexes. This aim will employ CD81 and PGRL mutagenesis, and biochemical techniques including MALDI-TOF MS to test the hypothesis that CD81 serves as a transmembrane adapter protein linking PGRL with an intracellular signaling protein. 3) Determine whether CD81 and/or PGRL interact with or regulate the activity of EP3. The affinity of EP3 will be tested in the presence or absence of antibody to CD81 or PGRL and tested under conditions which control the co-expression of PGRL and CD81 or in the presence of soluble PGRL. The coordinated effect of CD81, PGRL and EP3 on T cell integrin activity measured by adhesion to or motility on ICAMs.
描述(申请人提供):CD81是一种具有多种免疫调节功能的河豚毒素。在T细胞上,CD81抗体可激活LFA-1,并与TCR/CD3提供共刺激信号,促进T细胞活化。CD81抗体也可以阻止T细胞的早期发育。CD81-/-小鼠Th2反应受损,对过敏原诱导的呼吸道高反应性具有抵抗力。CD81是丙型肝炎病毒包膜蛋白E2的受体,其与CD81的结合作用与抗CD81抗体的作用相似。CD81调节T细胞活性的机制尚不清楚。最近发现,T细胞上的CD81与一个新的免疫球蛋白超家族成员PGRL有物理联系。PGRL可调节T细胞对前列腺素(PG)的反应。概括地说,这项提议寻求特定的PGs、CD81和通过LFA-I调节T细胞黏附和运动之间的联系的证据。具体地说,这个项目将:1)确定CD81介导的信号,导致T细胞上LFA-1的激活。棕榈酰化的作用和参与信号转导的特定支架蛋白的招募将被研究。使用流式细胞术和ICAM包被的荧光微球的一种新的LFA-1亲和力测定将用于识别CD81和LFA-1之间的信号中间体。2)明确CD81-PGRL络合物的结构和分子特征。这一目标将利用CD81和PGRL的突变,以及包括MALDI-TOF MS在内的生化技术来验证CD81作为跨膜适配器蛋白连接PGRL和细胞内信号蛋白的假设。3)确定CD81和/或PGRL是否与EP3相互作用或调节其活性。EP3的亲和力将在有或没有CD81或PGRL抗体的情况下进行测试,并在控制PGRL和CD81共表达的条件下或在可溶性PGRL存在的情况下进行测试。CD81、PGRL和EP3对ICAM上T细胞整合素活性的协同作用
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephen Keith Chapes其他文献
Stephen Keith Chapes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephen Keith Chapes', 18)}}的其他基金
Definition of host genes required for intracellular pathogen growth
细胞内病原体生长所需宿主基因的定义
- 批准号:
7874019 - 财政年份:2010
- 资助金额:
$ 24.86万 - 项目类别:
Definition of host genes required for intracellular pathogen growth
细胞内病原体生长所需宿主基因的定义
- 批准号:
8019012 - 财政年份:2010
- 资助金额:
$ 24.86万 - 项目类别:
Analysis of CD81-PGRL complex on T cells
T 细胞上 CD81-PGRL 复合物的分析
- 批准号:
6877169 - 财政年份:2003
- 资助金额:
$ 24.86万 - 项目类别:
Analysis of CD81-PGRL complex on T cells
T 细胞上 CD81-PGRL 复合物的分析
- 批准号:
6630118 - 财政年份:2003
- 资助金额:
$ 24.86万 - 项目类别:
相似海外基金
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
$ 24.86万 - 项目类别:
Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
$ 24.86万 - 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
$ 24.86万 - 项目类别:
University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
$ 24.86万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
$ 24.86万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
$ 24.86万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574978-2022 - 财政年份:2022
- 资助金额:
$ 24.86万 - 项目类别:
University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
$ 24.86万 - 项目类别:
Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
- 批准号:
RGPIN-2015-05491 - 财政年份:2021
- 资助金额:
$ 24.86万 - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
- 批准号:
RGPIN-2019-06980 - 财政年份:2021
- 资助金额:
$ 24.86万 - 项目类别:
Discovery Grants Program - Individual